2-Methyl-2-azabicyclo<2.2.2>oct-5-en | 3693-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Methyl-2-azabicyclo<2.2.2>oct-5-en
• 英文别名: N-Methyl-2-azabicyclo<2,2,2>oct-5-en；2-Azabicyclo(2.2.2)oct-5-ene, 2-methyl-；2-methyl-2-azabicyclo[2.2.2]oct-5-ene
• CAS: 3693-61-6
• 化学式: C₈H₁₃N
• 分子量: 123.198
• InChiKey: UOPYCKIZXXZAGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Methyl-2-azabicyclo<2.2.2>oct-5-en 在 K⁽¹⁺⁾*Cl₂I^(1-) 作用下， 以 氯仿 为溶剂， 以33%的产率得到6-iodo-1-methyl-1-azoniatricyclo[3.2.1.0^2,7]octane dichloroiodate(I)
  参考文献：
  名称：

  摘要：

  Addition of bromine and potassium dihaloiodates((1)) to 2-alkyl-2-azabicyclo[2.2.1]hept-5-enes and 2-alkyl-2-azabicyclo[2.2.2]oct-5-enes affords quaternary ammonium salts containing the aziridine ring and the polyhalide anion. The possibility of using these salts for the synthesis of 6-substituted 2-alkyl-2-azabicyclo[2.2.1]heptanes has been shown.

  DOI：

  10.1023/a:1020904630518
• 作为产物：
  描述：

  聚合甲醛 、 盐酸甲胺 、 1,3-环己二烯 以 水 为溶剂， 反应 84.0h， 以18%的产率得到2-Methyl-2-azabicyclo<2.2.2>oct-5-en
  参考文献：
  名称：

  2-氮杂双环-[2.2.1]庚基和-[2.2.2]辛基环系统的正甲基衍生物的NMR研究；动力学质子化确定Invertomer的偏好

  摘要：

  通过1 H，13 C和15 N NMR光谱研究标题化合物。由于即使在低温下，在NMR时间尺度上，氮气中的转化速度也很快，因此动力学质子化可用于估算环境温度下的转化体比率。Invertomer的偏爱似乎与空间因素的运作是一致的。

  DOI：

  10.1016/s0040-4020(01)91227-x

文献信息

• BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
  申请人：Lampe John W.

  公开号：US20110144150A1

  公开（公告）日：2011-06-16

  The present invention is directed to synthetic bridged bicyclic compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. The method comprises administering to a subject a therapeutically effective amount of a Rho kinase inhibitory compound of Formula I, wherein said amount is effective to influence the actomyosin interactions, for example, by leading to cellular relaxation and alterations in cell-substratum adhesions. In one embodiment, the method treats increased intraocular pressure, such as primary open-angle glaucoma. In another embodiment, the method treats diseases or conditions of the lung associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema.

  本发明涉及一种合成的桥接双环化合物，该化合物是rho相关蛋白激酶的抑制剂。本发明还涉及包括这些化合物和药用可接受载体的药物组合物。此外，本发明还涉及一种预防或治疗与细胞骨架重组相关的疾病或症状的方法。该方法包括向受试者施用一定量的具有治疗作用的公式I的Rho激酶抑制剂化合物，其中该量有效地影响肌动蛋白互作，例如，通过导致细胞松弛和细胞-基质粘附的改变。在一种实施方式中，该方法治疗增加的眼内压，如原发性开角青光眼。在另一种实施方式中，该方法治疗与肺部细胞过度增殖、重塑、炎症、血管收缩、支气管收缩、气道高反应性和水肿相关的疾病或症状。
• Regio- and Facial-Selective Effects of Allylic Heteroatoms in 1,3-Dipolar Cycloaddition of a Nitrile Oxide
  作者：Yoshinobu Inouye、Morihiro Mitsuya、Kenji Tokuhisa、Hiroshi Kakisawa

  DOI：10.1246/bcsj.63.3300

  日期：1990.11

  The 1,3-dipolar cycloaddition of nitrile oxides to 2-X-bicyclo[2.2.2]oct-5-enes (X=O, NMe, S, SO2) were investigated together with acyclic and alicyclic analogues. The regioselectivity in an exo-attack was controlled by the heteroatom present at an allylic position —a remote attack was predominant in the cases of O and SO2 but a vicinal attack in those of NMe and S— and the results were rationalized

  与无环和脂环类似物一起研究了腈氧化物与 2-X-双环 [2.2.2] oct-5-烯（X=O、NMe、S、SO2）的 1,3-偶极环加成反应。外向攻击中的区域选择性受烯丙基位置上的杂原子控制——远程攻击在 O 和 SO2 的情况下占主导地位，但在 NMe 和 S 的情况下是邻位攻击——结果从电子性质中得到了合理化杂原子 X。在内向攻击中，在每种情况下都观察到远程攻击，并且 X 与氧化腈的氧之间的偶极-偶极排斥被认为是主要因素。杂原子周围的空间环境控制着面部选择性。
• NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
  申请人：LERCHEN Hans-Georg

  公开号：US20130122024A1

  公开（公告）日：2013-05-16

  The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及针对靶向介质素的新型N，N-二烷基月桂酰基链霉素结合物（ADC），这些ADC的活性代谢物，制备这些ADC的过程，使用这些ADC治疗和/或预防疾病，以及使用这些ADC制造治疗和/或预防疾病的药物，更具体地说是治疗和/或预防肿瘤等高增殖和/或血管生成性疾病。这种治疗可以作为单一疗法，也可以与其他药物或进一步治疗措施结合使用。
• Fennhoff, Gerhard; Heesing, Albert, Chemische Berichte, 1989, vol. 122, p. 1153 - 1160
  作者：Fennhoff, Gerhard、Heesing, Albert

  DOI：——

  日期：——
• Model studies probing the amino-Claisen rearrangement approach to hydroisoquinoline synthesis. Development of methods for stereocontrolled introduction of reserpine E ring type functionality
  作者：Ellen W. Baxter、David Labaree、Shouchung Chao、Patrick S. Mariano

  DOI：10.1021/jo00273a024

  日期：1989.6